| Title |
Trifluoperazine versus placebo for schizophrenia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2014
|
| DOI | 10.1002/14651858.cd010226.pub2 |
| Pubmed ID | |
| Authors |
Kai Koch, Kamel Mansi, Euan Haynes, Clive E Adams, Stephanie Sampson, Vivek A Furtado |
| Abstract |
Trifluoperazine is a long-established high potency typical antipsychotic drug used in the treatment of schizophrenia and schizophrenia-like illnesses. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 14% |
| Spain | 2 | 14% |
| India | 1 | 7% |
| New Zealand | 1 | 7% |
| Unknown | 8 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 10 | 71% |
| Practitioners (doctors, other healthcare professionals) | 4 | 29% |
Mendeley readers
The data shown below were compiled from readership statistics for 274 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | <1% |
| Unknown | 272 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 48 | 18% |
| Student > Bachelor | 32 | 12% |
| Researcher | 29 | 11% |
| Student > Ph. D. Student | 25 | 9% |
| Student > Doctoral Student | 13 | 5% |
| Other | 36 | 13% |
| Unknown | 91 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 60 | 22% |
| Nursing and Health Professions | 28 | 10% |
| Psychology | 24 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 16 | 6% |
| Biochemistry, Genetics and Molecular Biology | 10 | 4% |
| Other | 37 | 14% |
| Unknown | 99 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 August 2020.
All research outputs
#1,931,791
of 25,595,500 outputs
Outputs from Cochrane database of systematic reviews
#4,163
of 13,156 outputs
Outputs of similar age
#21,274
of 320,465 outputs
Outputs of similar age from Cochrane database of systematic reviews
#86
of 242 outputs
Altmetric has tracked 25,595,500 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,465 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 242 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.